Global Cancer Registry Software
Global Cancer Registry Software

Cancer Registry Software Comprehensive Study by Type (Standalone Software, Integrated Software), Functionality (Cancer Reporting to Meet State & Federal Regulations, Patient Care Management, Product Outcome Evaluation, Medical Research and Clinical Studies), Database (Commercial Database, Public Databases), Deployment Model (On-Premise Models, Cloud-Based Models), End User (Government Organizations & Third-party Administrators (TPAS), Hospitals & Medical Practices, Pharmaceutical, Biotechnology, & Medical Device Companies, Private Payers, Research Centers) Players and Region - Global Market Outlook to 2026

Cancer Registry Software Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Feb 2021 Edition 208 Pages 188 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Cancer Registry Software Market?

A cancer registry software is a software that is designed for the collection, storage, and management of data on persons with cancer. Registries play a critical role in cancer surveillance, which tells us where the efforts to reduce the cancer burden. The data also serve as a foundation for cancer research and are used to plan and evaluate cancer prevention and control interventions. The cancer registry software market is expected to grow in the future due to increasingly favorable government initiatives and rising pressure to improve the quality of care.

The market study is being classified by Type (Standalone Software and Integrated Software) and major geographies with country level break-up.

Elekta (Sweden), Onco, Inc. (United States), CNET Global Solutions (United States), Rocky Mountain Cancer Data Systems (RMCDS) (United States), McKesson Corporation (United States), Electronic Registry Systems, Inc (United States), Conduent, Inc (United States), IBM (United States) and Himagine solutions inc (United States) are some of the key players profiled in the study.

The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Cancer Registry Software market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Cancer Registry Software market by Type, Application and Region.

On the basis of geography, the market of Cancer Registry Software has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Growing Prevalence of Cancer
  • Rising Pressure to Improve the Quality of Care and Reduce Healthcare Costs
  • Increasing Adoption of Electronic Healthcare Record Systems

Market Trend
  • Growth of Cloud-Based Cancer Patient Registry Solutions
  • Government Funding Initiatives to Encourage the Development of Cancer Registries

Restraints
  • Privacy and Data Security Concern

Opportunities
  • Rising Number of Accountable Care Organizations
  • High Investments in Healthcare IT

Challenges
  • Lack of Interoperability and Integration
  • Lack of Awareness


Market Leaders and some development strategies
In Jan 2018, Elekta announced it is collaborating with IBM Watson Health to offer Watson for Oncology with Elekta’s cancer care solutions. Under the terms of a new agreement, Elekta will sell Watson for Oncology beginning in early 2018 as a clinical decision support (CDS) solution paired within Elekta’s digital cancer care solutions, including the Mosaiq oncology information system (OIS).
In April 2018, Elekta announced that it is making a strategic investment in PalabraApps, LLC to advance the development of Elekta's clinical workflow productivity and mobility tools. Tools developed through this investment will provide customers with innovative solutions that are fully integrated with Elekta's MOSAIQ® Oncology Information System to address the growing need for enhanced clinical efficiency and quality control.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Cancer Registry Software Developer, Government Regulatory and Research Organizations and End-Use Industry

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Standalone Software
  • Integrated Software
By Functionality
  • Cancer Reporting to Meet State & Federal Regulations
  • Patient Care Management
  • Product Outcome Evaluation
  • Medical Research and Clinical Studies

By Database
  • Commercial Database
  • Public Databases

By Deployment Model
  • On-Premise Models
  • Cloud-Based Models

By End User
  • Government Organizations & Third-party Administrators (TPAS)
  • Hospitals & Medical Practices
  • Pharmaceutical, Biotechnology, & Medical Device Companies
  • Private Payers
  • Research Centers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence of Cancer
      • 3.2.2. Rising Pressure to Improve the Quality of Care and Reduce Healthcare Costs
      • 3.2.3. Increasing Adoption of Electronic Healthcare Record Systems
    • 3.3. Market Challenges
      • 3.3.1. Lack of Interoperability and Integration
      • 3.3.2. Lack of Awareness
    • 3.4. Market Trends
      • 3.4.1. Growth of Cloud-Based Cancer Patient Registry Solutions
      • 3.4.2. Government Funding Initiatives to Encourage the Development of Cancer Registries
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cancer Registry Software, by Type, Functionality, Database, Deployment Model, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Cancer Registry Software (Value)
      • 5.2.1. Global Cancer Registry Software by: Type (Value)
        • 5.2.1.1. Standalone Software
        • 5.2.1.2. Integrated Software
      • 5.2.2. Global Cancer Registry Software by: Functionality (Value)
        • 5.2.2.1. Cancer Reporting to Meet State & Federal Regulations
        • 5.2.2.2. Patient Care Management
        • 5.2.2.3. Product Outcome Evaluation
        • 5.2.2.4. Medical Research and Clinical Studies
      • 5.2.3. Global Cancer Registry Software by: Database (Value)
        • 5.2.3.1. Commercial Database
        • 5.2.3.2. Public Databases
      • 5.2.4. Global Cancer Registry Software by: Deployment Model (Value)
        • 5.2.4.1. On-Premise Models
        • 5.2.4.2. Cloud-Based Models
      • 5.2.5. Global Cancer Registry Software by: End User (Value)
        • 5.2.5.1. Government Organizations & Third-party Administrators (TPAS)
        • 5.2.5.2. Hospitals & Medical Practices
        • 5.2.5.3. Pharmaceutical, Biotechnology, & Medical Device Companies
        • 5.2.5.4. Private Payers
        • 5.2.5.5. Research Centers
      • 5.2.6. Global Cancer Registry Software Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Cancer Registry Software (Price)
      • 5.3.1. Global Cancer Registry Software by: Type (Price)
  • 6. Cancer Registry Software: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Elekta (Sweden)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Onco, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. CNET Global Solutions (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Rocky Mountain Cancer Data Systems (RMCDS) (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. McKesson Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Electronic Registry Systems, Inc (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Conduent, Inc (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. IBM (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Himagine solutions inc (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Cancer Registry Software Sale, by Type, Functionality, Database, Deployment Model, End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Cancer Registry Software (Value)
      • 7.2.1. Global Cancer Registry Software by: Type (Value)
        • 7.2.1.1. Standalone Software
        • 7.2.1.2. Integrated Software
      • 7.2.2. Global Cancer Registry Software by: Functionality (Value)
        • 7.2.2.1. Cancer Reporting to Meet State & Federal Regulations
        • 7.2.2.2. Patient Care Management
        • 7.2.2.3. Product Outcome Evaluation
        • 7.2.2.4. Medical Research and Clinical Studies
      • 7.2.3. Global Cancer Registry Software by: Database (Value)
        • 7.2.3.1. Commercial Database
        • 7.2.3.2. Public Databases
      • 7.2.4. Global Cancer Registry Software by: Deployment Model (Value)
        • 7.2.4.1. On-Premise Models
        • 7.2.4.2. Cloud-Based Models
      • 7.2.5. Global Cancer Registry Software by: End User (Value)
        • 7.2.5.1. Government Organizations & Third-party Administrators (TPAS)
        • 7.2.5.2. Hospitals & Medical Practices
        • 7.2.5.3. Pharmaceutical, Biotechnology, & Medical Device Companies
        • 7.2.5.4. Private Payers
        • 7.2.5.5. Research Centers
      • 7.2.6. Global Cancer Registry Software Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Cancer Registry Software (Price)
      • 7.3.1. Global Cancer Registry Software by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cancer Registry Software: by Type(USD Million)
  • Table 2. Cancer Registry Software Standalone Software , by Region USD Million (2015-2020)
  • Table 3. Cancer Registry Software Integrated Software , by Region USD Million (2015-2020)
  • Table 4. Cancer Registry Software: by Functionality(USD Million)
  • Table 5. Cancer Registry Software Cancer Reporting to Meet State & Federal Regulations , by Region USD Million (2015-2020)
  • Table 6. Cancer Registry Software Patient Care Management , by Region USD Million (2015-2020)
  • Table 7. Cancer Registry Software Product Outcome Evaluation , by Region USD Million (2015-2020)
  • Table 8. Cancer Registry Software Medical Research and Clinical Studies , by Region USD Million (2015-2020)
  • Table 9. Cancer Registry Software: by Database(USD Million)
  • Table 10. Cancer Registry Software Commercial Database , by Region USD Million (2015-2020)
  • Table 11. Cancer Registry Software Public Databases , by Region USD Million (2015-2020)
  • Table 12. Cancer Registry Software: by Deployment Model(USD Million)
  • Table 13. Cancer Registry Software On-Premise Models , by Region USD Million (2015-2020)
  • Table 14. Cancer Registry Software Cloud-Based Models , by Region USD Million (2015-2020)
  • Table 15. Cancer Registry Software: by End User(USD Million)
  • Table 16. Cancer Registry Software Government Organizations & Third-party Administrators (TPAS) , by Region USD Million (2015-2020)
  • Table 17. Cancer Registry Software Hospitals & Medical Practices , by Region USD Million (2015-2020)
  • Table 18. Cancer Registry Software Pharmaceutical, Biotechnology, & Medical Device Companies , by Region USD Million (2015-2020)
  • Table 19. Cancer Registry Software Private Payers , by Region USD Million (2015-2020)
  • Table 20. Cancer Registry Software Research Centers , by Region USD Million (2015-2020)
  • Table 21. South America Cancer Registry Software, by Country USD Million (2015-2020)
  • Table 22. South America Cancer Registry Software, by Type USD Million (2015-2020)
  • Table 23. South America Cancer Registry Software, by Functionality USD Million (2015-2020)
  • Table 24. South America Cancer Registry Software, by Database USD Million (2015-2020)
  • Table 25. South America Cancer Registry Software, by Deployment Model USD Million (2015-2020)
  • Table 26. South America Cancer Registry Software, by End User USD Million (2015-2020)
  • Table 27. Brazil Cancer Registry Software, by Type USD Million (2015-2020)
  • Table 28. Brazil Cancer Registry Software, by Functionality USD Million (2015-2020)
  • Table 29. Brazil Cancer Registry Software, by Database USD Million (2015-2020)
  • Table 30. Brazil Cancer Registry Software, by Deployment Model USD Million (2015-2020)
  • Table 31. Brazil Cancer Registry Software, by End User USD Million (2015-2020)
  • Table 32. Argentina Cancer Registry Software, by Type USD Million (2015-2020)
  • Table 33. Argentina Cancer Registry Software, by Functionality USD Million (2015-2020)
  • Table 34. Argentina Cancer Registry Software, by Database USD Million (2015-2020)
  • Table 35. Argentina Cancer Registry Software, by Deployment Model USD Million (2015-2020)
  • Table 36. Argentina Cancer Registry Software, by End User USD Million (2015-2020)
  • Table 37. Rest of South America Cancer Registry Software, by Type USD Million (2015-2020)
  • Table 38. Rest of South America Cancer Registry Software, by Functionality USD Million (2015-2020)
  • Table 39. Rest of South America Cancer Registry Software, by Database USD Million (2015-2020)
  • Table 40. Rest of South America Cancer Registry Software, by Deployment Model USD Million (2015-2020)
  • Table 41. Rest of South America Cancer Registry Software, by End User USD Million (2015-2020)
  • Table 42. Asia Pacific Cancer Registry Software, by Country USD Million (2015-2020)
  • Table 43. Asia Pacific Cancer Registry Software, by Type USD Million (2015-2020)
  • Table 44. Asia Pacific Cancer Registry Software, by Functionality USD Million (2015-2020)
  • Table 45. Asia Pacific Cancer Registry Software, by Database USD Million (2015-2020)
  • Table 46. Asia Pacific Cancer Registry Software, by Deployment Model USD Million (2015-2020)
  • Table 47. Asia Pacific Cancer Registry Software, by End User USD Million (2015-2020)
  • Table 48. China Cancer Registry Software, by Type USD Million (2015-2020)
  • Table 49. China Cancer Registry Software, by Functionality USD Million (2015-2020)
  • Table 50. China Cancer Registry Software, by Database USD Million (2015-2020)
  • Table 51. China Cancer Registry Software, by Deployment Model USD Million (2015-2020)
  • Table 52. China Cancer Registry Software, by End User USD Million (2015-2020)
  • Table 53. Japan Cancer Registry Software, by Type USD Million (2015-2020)
  • Table 54. Japan Cancer Registry Software, by Functionality USD Million (2015-2020)
  • Table 55. Japan Cancer Registry Software, by Database USD Million (2015-2020)
  • Table 56. Japan Cancer Registry Software, by Deployment Model USD Million (2015-2020)
  • Table 57. Japan Cancer Registry Software, by End User USD Million (2015-2020)
  • Table 58. India Cancer Registry Software, by Type USD Million (2015-2020)
  • Table 59. India Cancer Registry Software, by Functionality USD Million (2015-2020)
  • Table 60. India Cancer Registry Software, by Database USD Million (2015-2020)
  • Table 61. India Cancer Registry Software, by Deployment Model USD Million (2015-2020)
  • Table 62. India Cancer Registry Software, by End User USD Million (2015-2020)
  • Table 63. South Korea Cancer Registry Software, by Type USD Million (2015-2020)
  • Table 64. South Korea Cancer Registry Software, by Functionality USD Million (2015-2020)
  • Table 65. South Korea Cancer Registry Software, by Database USD Million (2015-2020)
  • Table 66. South Korea Cancer Registry Software, by Deployment Model USD Million (2015-2020)
  • Table 67. South Korea Cancer Registry Software, by End User USD Million (2015-2020)
  • Table 68. Taiwan Cancer Registry Software, by Type USD Million (2015-2020)
  • Table 69. Taiwan Cancer Registry Software, by Functionality USD Million (2015-2020)
  • Table 70. Taiwan Cancer Registry Software, by Database USD Million (2015-2020)
  • Table 71. Taiwan Cancer Registry Software, by Deployment Model USD Million (2015-2020)
  • Table 72. Taiwan Cancer Registry Software, by End User USD Million (2015-2020)
  • Table 73. Australia Cancer Registry Software, by Type USD Million (2015-2020)
  • Table 74. Australia Cancer Registry Software, by Functionality USD Million (2015-2020)
  • Table 75. Australia Cancer Registry Software, by Database USD Million (2015-2020)
  • Table 76. Australia Cancer Registry Software, by Deployment Model USD Million (2015-2020)
  • Table 77. Australia Cancer Registry Software, by End User USD Million (2015-2020)
  • Table 78. Rest of Asia-Pacific Cancer Registry Software, by Type USD Million (2015-2020)
  • Table 79. Rest of Asia-Pacific Cancer Registry Software, by Functionality USD Million (2015-2020)
  • Table 80. Rest of Asia-Pacific Cancer Registry Software, by Database USD Million (2015-2020)
  • Table 81. Rest of Asia-Pacific Cancer Registry Software, by Deployment Model USD Million (2015-2020)
  • Table 82. Rest of Asia-Pacific Cancer Registry Software, by End User USD Million (2015-2020)
  • Table 83. Europe Cancer Registry Software, by Country USD Million (2015-2020)
  • Table 84. Europe Cancer Registry Software, by Type USD Million (2015-2020)
  • Table 85. Europe Cancer Registry Software, by Functionality USD Million (2015-2020)
  • Table 86. Europe Cancer Registry Software, by Database USD Million (2015-2020)
  • Table 87. Europe Cancer Registry Software, by Deployment Model USD Million (2015-2020)
  • Table 88. Europe Cancer Registry Software, by End User USD Million (2015-2020)
  • Table 89. Germany Cancer Registry Software, by Type USD Million (2015-2020)
  • Table 90. Germany Cancer Registry Software, by Functionality USD Million (2015-2020)
  • Table 91. Germany Cancer Registry Software, by Database USD Million (2015-2020)
  • Table 92. Germany Cancer Registry Software, by Deployment Model USD Million (2015-2020)
  • Table 93. Germany Cancer Registry Software, by End User USD Million (2015-2020)
  • Table 94. France Cancer Registry Software, by Type USD Million (2015-2020)
  • Table 95. France Cancer Registry Software, by Functionality USD Million (2015-2020)
  • Table 96. France Cancer Registry Software, by Database USD Million (2015-2020)
  • Table 97. France Cancer Registry Software, by Deployment Model USD Million (2015-2020)
  • Table 98. France Cancer Registry Software, by End User USD Million (2015-2020)
  • Table 99. Italy Cancer Registry Software, by Type USD Million (2015-2020)
  • Table 100. Italy Cancer Registry Software, by Functionality USD Million (2015-2020)
  • Table 101. Italy Cancer Registry Software, by Database USD Million (2015-2020)
  • Table 102. Italy Cancer Registry Software, by Deployment Model USD Million (2015-2020)
  • Table 103. Italy Cancer Registry Software, by End User USD Million (2015-2020)
  • Table 104. United Kingdom Cancer Registry Software, by Type USD Million (2015-2020)
  • Table 105. United Kingdom Cancer Registry Software, by Functionality USD Million (2015-2020)
  • Table 106. United Kingdom Cancer Registry Software, by Database USD Million (2015-2020)
  • Table 107. United Kingdom Cancer Registry Software, by Deployment Model USD Million (2015-2020)
  • Table 108. United Kingdom Cancer Registry Software, by End User USD Million (2015-2020)
  • Table 109. Netherlands Cancer Registry Software, by Type USD Million (2015-2020)
  • Table 110. Netherlands Cancer Registry Software, by Functionality USD Million (2015-2020)
  • Table 111. Netherlands Cancer Registry Software, by Database USD Million (2015-2020)
  • Table 112. Netherlands Cancer Registry Software, by Deployment Model USD Million (2015-2020)
  • Table 113. Netherlands Cancer Registry Software, by End User USD Million (2015-2020)
  • Table 114. Rest of Europe Cancer Registry Software, by Type USD Million (2015-2020)
  • Table 115. Rest of Europe Cancer Registry Software, by Functionality USD Million (2015-2020)
  • Table 116. Rest of Europe Cancer Registry Software, by Database USD Million (2015-2020)
  • Table 117. Rest of Europe Cancer Registry Software, by Deployment Model USD Million (2015-2020)
  • Table 118. Rest of Europe Cancer Registry Software, by End User USD Million (2015-2020)
  • Table 119. MEA Cancer Registry Software, by Country USD Million (2015-2020)
  • Table 120. MEA Cancer Registry Software, by Type USD Million (2015-2020)
  • Table 121. MEA Cancer Registry Software, by Functionality USD Million (2015-2020)
  • Table 122. MEA Cancer Registry Software, by Database USD Million (2015-2020)
  • Table 123. MEA Cancer Registry Software, by Deployment Model USD Million (2015-2020)
  • Table 124. MEA Cancer Registry Software, by End User USD Million (2015-2020)
  • Table 125. Middle East Cancer Registry Software, by Type USD Million (2015-2020)
  • Table 126. Middle East Cancer Registry Software, by Functionality USD Million (2015-2020)
  • Table 127. Middle East Cancer Registry Software, by Database USD Million (2015-2020)
  • Table 128. Middle East Cancer Registry Software, by Deployment Model USD Million (2015-2020)
  • Table 129. Middle East Cancer Registry Software, by End User USD Million (2015-2020)
  • Table 130. Africa Cancer Registry Software, by Type USD Million (2015-2020)
  • Table 131. Africa Cancer Registry Software, by Functionality USD Million (2015-2020)
  • Table 132. Africa Cancer Registry Software, by Database USD Million (2015-2020)
  • Table 133. Africa Cancer Registry Software, by Deployment Model USD Million (2015-2020)
  • Table 134. Africa Cancer Registry Software, by End User USD Million (2015-2020)
  • Table 135. North America Cancer Registry Software, by Country USD Million (2015-2020)
  • Table 136. North America Cancer Registry Software, by Type USD Million (2015-2020)
  • Table 137. North America Cancer Registry Software, by Functionality USD Million (2015-2020)
  • Table 138. North America Cancer Registry Software, by Database USD Million (2015-2020)
  • Table 139. North America Cancer Registry Software, by Deployment Model USD Million (2015-2020)
  • Table 140. North America Cancer Registry Software, by End User USD Million (2015-2020)
  • Table 141. United States Cancer Registry Software, by Type USD Million (2015-2020)
  • Table 142. United States Cancer Registry Software, by Functionality USD Million (2015-2020)
  • Table 143. United States Cancer Registry Software, by Database USD Million (2015-2020)
  • Table 144. United States Cancer Registry Software, by Deployment Model USD Million (2015-2020)
  • Table 145. United States Cancer Registry Software, by End User USD Million (2015-2020)
  • Table 146. Canada Cancer Registry Software, by Type USD Million (2015-2020)
  • Table 147. Canada Cancer Registry Software, by Functionality USD Million (2015-2020)
  • Table 148. Canada Cancer Registry Software, by Database USD Million (2015-2020)
  • Table 149. Canada Cancer Registry Software, by Deployment Model USD Million (2015-2020)
  • Table 150. Canada Cancer Registry Software, by End User USD Million (2015-2020)
  • Table 151. Mexico Cancer Registry Software, by Type USD Million (2015-2020)
  • Table 152. Mexico Cancer Registry Software, by Functionality USD Million (2015-2020)
  • Table 153. Mexico Cancer Registry Software, by Database USD Million (2015-2020)
  • Table 154. Mexico Cancer Registry Software, by Deployment Model USD Million (2015-2020)
  • Table 155. Mexico Cancer Registry Software, by End User USD Million (2015-2020)
  • Table 156. Cancer Registry Software: by Type(USD/Units)
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Cancer Registry Software: by Type(USD Million)
  • Table 167. Cancer Registry Software Standalone Software , by Region USD Million (2021-2026)
  • Table 168. Cancer Registry Software Integrated Software , by Region USD Million (2021-2026)
  • Table 169. Cancer Registry Software: by Functionality(USD Million)
  • Table 170. Cancer Registry Software Cancer Reporting to Meet State & Federal Regulations , by Region USD Million (2021-2026)
  • Table 171. Cancer Registry Software Patient Care Management , by Region USD Million (2021-2026)
  • Table 172. Cancer Registry Software Product Outcome Evaluation , by Region USD Million (2021-2026)
  • Table 173. Cancer Registry Software Medical Research and Clinical Studies , by Region USD Million (2021-2026)
  • Table 174. Cancer Registry Software: by Database(USD Million)
  • Table 175. Cancer Registry Software Commercial Database , by Region USD Million (2021-2026)
  • Table 176. Cancer Registry Software Public Databases , by Region USD Million (2021-2026)
  • Table 177. Cancer Registry Software: by Deployment Model(USD Million)
  • Table 178. Cancer Registry Software On-Premise Models , by Region USD Million (2021-2026)
  • Table 179. Cancer Registry Software Cloud-Based Models , by Region USD Million (2021-2026)
  • Table 180. Cancer Registry Software: by End User(USD Million)
  • Table 181. Cancer Registry Software Government Organizations & Third-party Administrators (TPAS) , by Region USD Million (2021-2026)
  • Table 182. Cancer Registry Software Hospitals & Medical Practices , by Region USD Million (2021-2026)
  • Table 183. Cancer Registry Software Pharmaceutical, Biotechnology, & Medical Device Companies , by Region USD Million (2021-2026)
  • Table 184. Cancer Registry Software Private Payers , by Region USD Million (2021-2026)
  • Table 185. Cancer Registry Software Research Centers , by Region USD Million (2021-2026)
  • Table 186. South America Cancer Registry Software, by Country USD Million (2021-2026)
  • Table 187. South America Cancer Registry Software, by Type USD Million (2021-2026)
  • Table 188. South America Cancer Registry Software, by Functionality USD Million (2021-2026)
  • Table 189. South America Cancer Registry Software, by Database USD Million (2021-2026)
  • Table 190. South America Cancer Registry Software, by Deployment Model USD Million (2021-2026)
  • Table 191. South America Cancer Registry Software, by End User USD Million (2021-2026)
  • Table 192. Brazil Cancer Registry Software, by Type USD Million (2021-2026)
  • Table 193. Brazil Cancer Registry Software, by Functionality USD Million (2021-2026)
  • Table 194. Brazil Cancer Registry Software, by Database USD Million (2021-2026)
  • Table 195. Brazil Cancer Registry Software, by Deployment Model USD Million (2021-2026)
  • Table 196. Brazil Cancer Registry Software, by End User USD Million (2021-2026)
  • Table 197. Argentina Cancer Registry Software, by Type USD Million (2021-2026)
  • Table 198. Argentina Cancer Registry Software, by Functionality USD Million (2021-2026)
  • Table 199. Argentina Cancer Registry Software, by Database USD Million (2021-2026)
  • Table 200. Argentina Cancer Registry Software, by Deployment Model USD Million (2021-2026)
  • Table 201. Argentina Cancer Registry Software, by End User USD Million (2021-2026)
  • Table 202. Rest of South America Cancer Registry Software, by Type USD Million (2021-2026)
  • Table 203. Rest of South America Cancer Registry Software, by Functionality USD Million (2021-2026)
  • Table 204. Rest of South America Cancer Registry Software, by Database USD Million (2021-2026)
  • Table 205. Rest of South America Cancer Registry Software, by Deployment Model USD Million (2021-2026)
  • Table 206. Rest of South America Cancer Registry Software, by End User USD Million (2021-2026)
  • Table 207. Asia Pacific Cancer Registry Software, by Country USD Million (2021-2026)
  • Table 208. Asia Pacific Cancer Registry Software, by Type USD Million (2021-2026)
  • Table 209. Asia Pacific Cancer Registry Software, by Functionality USD Million (2021-2026)
  • Table 210. Asia Pacific Cancer Registry Software, by Database USD Million (2021-2026)
  • Table 211. Asia Pacific Cancer Registry Software, by Deployment Model USD Million (2021-2026)
  • Table 212. Asia Pacific Cancer Registry Software, by End User USD Million (2021-2026)
  • Table 213. China Cancer Registry Software, by Type USD Million (2021-2026)
  • Table 214. China Cancer Registry Software, by Functionality USD Million (2021-2026)
  • Table 215. China Cancer Registry Software, by Database USD Million (2021-2026)
  • Table 216. China Cancer Registry Software, by Deployment Model USD Million (2021-2026)
  • Table 217. China Cancer Registry Software, by End User USD Million (2021-2026)
  • Table 218. Japan Cancer Registry Software, by Type USD Million (2021-2026)
  • Table 219. Japan Cancer Registry Software, by Functionality USD Million (2021-2026)
  • Table 220. Japan Cancer Registry Software, by Database USD Million (2021-2026)
  • Table 221. Japan Cancer Registry Software, by Deployment Model USD Million (2021-2026)
  • Table 222. Japan Cancer Registry Software, by End User USD Million (2021-2026)
  • Table 223. India Cancer Registry Software, by Type USD Million (2021-2026)
  • Table 224. India Cancer Registry Software, by Functionality USD Million (2021-2026)
  • Table 225. India Cancer Registry Software, by Database USD Million (2021-2026)
  • Table 226. India Cancer Registry Software, by Deployment Model USD Million (2021-2026)
  • Table 227. India Cancer Registry Software, by End User USD Million (2021-2026)
  • Table 228. South Korea Cancer Registry Software, by Type USD Million (2021-2026)
  • Table 229. South Korea Cancer Registry Software, by Functionality USD Million (2021-2026)
  • Table 230. South Korea Cancer Registry Software, by Database USD Million (2021-2026)
  • Table 231. South Korea Cancer Registry Software, by Deployment Model USD Million (2021-2026)
  • Table 232. South Korea Cancer Registry Software, by End User USD Million (2021-2026)
  • Table 233. Taiwan Cancer Registry Software, by Type USD Million (2021-2026)
  • Table 234. Taiwan Cancer Registry Software, by Functionality USD Million (2021-2026)
  • Table 235. Taiwan Cancer Registry Software, by Database USD Million (2021-2026)
  • Table 236. Taiwan Cancer Registry Software, by Deployment Model USD Million (2021-2026)
  • Table 237. Taiwan Cancer Registry Software, by End User USD Million (2021-2026)
  • Table 238. Australia Cancer Registry Software, by Type USD Million (2021-2026)
  • Table 239. Australia Cancer Registry Software, by Functionality USD Million (2021-2026)
  • Table 240. Australia Cancer Registry Software, by Database USD Million (2021-2026)
  • Table 241. Australia Cancer Registry Software, by Deployment Model USD Million (2021-2026)
  • Table 242. Australia Cancer Registry Software, by End User USD Million (2021-2026)
  • Table 243. Rest of Asia-Pacific Cancer Registry Software, by Type USD Million (2021-2026)
  • Table 244. Rest of Asia-Pacific Cancer Registry Software, by Functionality USD Million (2021-2026)
  • Table 245. Rest of Asia-Pacific Cancer Registry Software, by Database USD Million (2021-2026)
  • Table 246. Rest of Asia-Pacific Cancer Registry Software, by Deployment Model USD Million (2021-2026)
  • Table 247. Rest of Asia-Pacific Cancer Registry Software, by End User USD Million (2021-2026)
  • Table 248. Europe Cancer Registry Software, by Country USD Million (2021-2026)
  • Table 249. Europe Cancer Registry Software, by Type USD Million (2021-2026)
  • Table 250. Europe Cancer Registry Software, by Functionality USD Million (2021-2026)
  • Table 251. Europe Cancer Registry Software, by Database USD Million (2021-2026)
  • Table 252. Europe Cancer Registry Software, by Deployment Model USD Million (2021-2026)
  • Table 253. Europe Cancer Registry Software, by End User USD Million (2021-2026)
  • Table 254. Germany Cancer Registry Software, by Type USD Million (2021-2026)
  • Table 255. Germany Cancer Registry Software, by Functionality USD Million (2021-2026)
  • Table 256. Germany Cancer Registry Software, by Database USD Million (2021-2026)
  • Table 257. Germany Cancer Registry Software, by Deployment Model USD Million (2021-2026)
  • Table 258. Germany Cancer Registry Software, by End User USD Million (2021-2026)
  • Table 259. France Cancer Registry Software, by Type USD Million (2021-2026)
  • Table 260. France Cancer Registry Software, by Functionality USD Million (2021-2026)
  • Table 261. France Cancer Registry Software, by Database USD Million (2021-2026)
  • Table 262. France Cancer Registry Software, by Deployment Model USD Million (2021-2026)
  • Table 263. France Cancer Registry Software, by End User USD Million (2021-2026)
  • Table 264. Italy Cancer Registry Software, by Type USD Million (2021-2026)
  • Table 265. Italy Cancer Registry Software, by Functionality USD Million (2021-2026)
  • Table 266. Italy Cancer Registry Software, by Database USD Million (2021-2026)
  • Table 267. Italy Cancer Registry Software, by Deployment Model USD Million (2021-2026)
  • Table 268. Italy Cancer Registry Software, by End User USD Million (2021-2026)
  • Table 269. United Kingdom Cancer Registry Software, by Type USD Million (2021-2026)
  • Table 270. United Kingdom Cancer Registry Software, by Functionality USD Million (2021-2026)
  • Table 271. United Kingdom Cancer Registry Software, by Database USD Million (2021-2026)
  • Table 272. United Kingdom Cancer Registry Software, by Deployment Model USD Million (2021-2026)
  • Table 273. United Kingdom Cancer Registry Software, by End User USD Million (2021-2026)
  • Table 274. Netherlands Cancer Registry Software, by Type USD Million (2021-2026)
  • Table 275. Netherlands Cancer Registry Software, by Functionality USD Million (2021-2026)
  • Table 276. Netherlands Cancer Registry Software, by Database USD Million (2021-2026)
  • Table 277. Netherlands Cancer Registry Software, by Deployment Model USD Million (2021-2026)
  • Table 278. Netherlands Cancer Registry Software, by End User USD Million (2021-2026)
  • Table 279. Rest of Europe Cancer Registry Software, by Type USD Million (2021-2026)
  • Table 280. Rest of Europe Cancer Registry Software, by Functionality USD Million (2021-2026)
  • Table 281. Rest of Europe Cancer Registry Software, by Database USD Million (2021-2026)
  • Table 282. Rest of Europe Cancer Registry Software, by Deployment Model USD Million (2021-2026)
  • Table 283. Rest of Europe Cancer Registry Software, by End User USD Million (2021-2026)
  • Table 284. MEA Cancer Registry Software, by Country USD Million (2021-2026)
  • Table 285. MEA Cancer Registry Software, by Type USD Million (2021-2026)
  • Table 286. MEA Cancer Registry Software, by Functionality USD Million (2021-2026)
  • Table 287. MEA Cancer Registry Software, by Database USD Million (2021-2026)
  • Table 288. MEA Cancer Registry Software, by Deployment Model USD Million (2021-2026)
  • Table 289. MEA Cancer Registry Software, by End User USD Million (2021-2026)
  • Table 290. Middle East Cancer Registry Software, by Type USD Million (2021-2026)
  • Table 291. Middle East Cancer Registry Software, by Functionality USD Million (2021-2026)
  • Table 292. Middle East Cancer Registry Software, by Database USD Million (2021-2026)
  • Table 293. Middle East Cancer Registry Software, by Deployment Model USD Million (2021-2026)
  • Table 294. Middle East Cancer Registry Software, by End User USD Million (2021-2026)
  • Table 295. Africa Cancer Registry Software, by Type USD Million (2021-2026)
  • Table 296. Africa Cancer Registry Software, by Functionality USD Million (2021-2026)
  • Table 297. Africa Cancer Registry Software, by Database USD Million (2021-2026)
  • Table 298. Africa Cancer Registry Software, by Deployment Model USD Million (2021-2026)
  • Table 299. Africa Cancer Registry Software, by End User USD Million (2021-2026)
  • Table 300. North America Cancer Registry Software, by Country USD Million (2021-2026)
  • Table 301. North America Cancer Registry Software, by Type USD Million (2021-2026)
  • Table 302. North America Cancer Registry Software, by Functionality USD Million (2021-2026)
  • Table 303. North America Cancer Registry Software, by Database USD Million (2021-2026)
  • Table 304. North America Cancer Registry Software, by Deployment Model USD Million (2021-2026)
  • Table 305. North America Cancer Registry Software, by End User USD Million (2021-2026)
  • Table 306. United States Cancer Registry Software, by Type USD Million (2021-2026)
  • Table 307. United States Cancer Registry Software, by Functionality USD Million (2021-2026)
  • Table 308. United States Cancer Registry Software, by Database USD Million (2021-2026)
  • Table 309. United States Cancer Registry Software, by Deployment Model USD Million (2021-2026)
  • Table 310. United States Cancer Registry Software, by End User USD Million (2021-2026)
  • Table 311. Canada Cancer Registry Software, by Type USD Million (2021-2026)
  • Table 312. Canada Cancer Registry Software, by Functionality USD Million (2021-2026)
  • Table 313. Canada Cancer Registry Software, by Database USD Million (2021-2026)
  • Table 314. Canada Cancer Registry Software, by Deployment Model USD Million (2021-2026)
  • Table 315. Canada Cancer Registry Software, by End User USD Million (2021-2026)
  • Table 316. Mexico Cancer Registry Software, by Type USD Million (2021-2026)
  • Table 317. Mexico Cancer Registry Software, by Functionality USD Million (2021-2026)
  • Table 318. Mexico Cancer Registry Software, by Database USD Million (2021-2026)
  • Table 319. Mexico Cancer Registry Software, by Deployment Model USD Million (2021-2026)
  • Table 320. Mexico Cancer Registry Software, by End User USD Million (2021-2026)
  • Table 321. Cancer Registry Software: by Type(USD/Units)
  • Table 322. Research Programs/Design for This Report
  • Table 323. Key Data Information from Secondary Sources
  • Table 324. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cancer Registry Software: by Type USD Million (2015-2020)
  • Figure 5. Global Cancer Registry Software: by Functionality USD Million (2015-2020)
  • Figure 6. Global Cancer Registry Software: by Database USD Million (2015-2020)
  • Figure 7. Global Cancer Registry Software: by Deployment Model USD Million (2015-2020)
  • Figure 8. Global Cancer Registry Software: by End User USD Million (2015-2020)
  • Figure 9. South America Cancer Registry Software Share (%), by Country
  • Figure 10. Asia Pacific Cancer Registry Software Share (%), by Country
  • Figure 11. Europe Cancer Registry Software Share (%), by Country
  • Figure 12. MEA Cancer Registry Software Share (%), by Country
  • Figure 13. North America Cancer Registry Software Share (%), by Country
  • Figure 14. Global Cancer Registry Software: by Type USD/Units (2015-2020)
  • Figure 15. Global Cancer Registry Software share by Players 2020 (%)
  • Figure 16. Global Cancer Registry Software share by Players (Top 3) 2020(%)
  • Figure 17. Global Cancer Registry Software share by Players (Top 5) 2020(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Elekta (Sweden) Revenue, Net Income and Gross profit
  • Figure 20. Elekta (Sweden) Revenue: by Geography 2020
  • Figure 21. Onco, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Onco, Inc. (United States) Revenue: by Geography 2020
  • Figure 23. CNET Global Solutions (United States) Revenue, Net Income and Gross profit
  • Figure 24. CNET Global Solutions (United States) Revenue: by Geography 2020
  • Figure 25. Rocky Mountain Cancer Data Systems (RMCDS) (United States) Revenue, Net Income and Gross profit
  • Figure 26. Rocky Mountain Cancer Data Systems (RMCDS) (United States) Revenue: by Geography 2020
  • Figure 27. McKesson Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 28. McKesson Corporation (United States) Revenue: by Geography 2020
  • Figure 29. Electronic Registry Systems, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 30. Electronic Registry Systems, Inc (United States) Revenue: by Geography 2020
  • Figure 31. Conduent, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 32. Conduent, Inc (United States) Revenue: by Geography 2020
  • Figure 33. IBM (United States) Revenue, Net Income and Gross profit
  • Figure 34. IBM (United States) Revenue: by Geography 2020
  • Figure 35. Himagine solutions inc (United States) Revenue, Net Income and Gross profit
  • Figure 36. Himagine solutions inc (United States) Revenue: by Geography 2020
  • Figure 37. Global Cancer Registry Software: by Type USD Million (2021-2026)
  • Figure 38. Global Cancer Registry Software: by Functionality USD Million (2021-2026)
  • Figure 39. Global Cancer Registry Software: by Database USD Million (2021-2026)
  • Figure 40. Global Cancer Registry Software: by Deployment Model USD Million (2021-2026)
  • Figure 41. Global Cancer Registry Software: by End User USD Million (2021-2026)
  • Figure 42. South America Cancer Registry Software Share (%), by Country
  • Figure 43. Asia Pacific Cancer Registry Software Share (%), by Country
  • Figure 44. Europe Cancer Registry Software Share (%), by Country
  • Figure 45. MEA Cancer Registry Software Share (%), by Country
  • Figure 46. North America Cancer Registry Software Share (%), by Country
  • Figure 47. Global Cancer Registry Software: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Elekta (Sweden)
  • Onco, Inc. (United States)
  • CNET Global Solutions (United States)
  • Rocky Mountain Cancer Data Systems (RMCDS) (United States)
  • McKesson Corporation (United States)
  • Electronic Registry Systems, Inc (United States)
  • Conduent, Inc (United States)
  • IBM (United States)
  • Himagine solutions inc (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation